Literature DB >> 33252984

Lack of Bacterial Colonization Measure in Randomized Controlled Trial on Inhaled Corticosteroids Effect in Patients with Chronic Obstructive Pulmonary Disease.

Miguel Angel Martinez-Garcia1,2, Alvar Agustí2,3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33252984      PMCID: PMC7924565          DOI: 10.1164/rccm.202011-4044LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


× No keyword cloud information.
To the Editor: We read with great interest the article by Han and colleagues on the effect of inhaled corticosteroids (ICS) withdrawal and baseline inhaled treatment in the IMPACT (Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD) study (1) as well as the three accompanying editorials on the topic (2–4) recently published in the Journal. Remarkably, most of the included patients in this study had severe chronic obstructive pulmonary disease (COPD) or had previous exacerbations (5). We would like to contribute to this debate by highlighting the following potentially relevant, but completely ignored, confounding factor: the role of bacterial colonization in these patients. This is based on the following observations: 1) between 25% and 50% of patients with COPD (especially those with severe disease or multiple exacerbations) suffer chronic bronchial colonization, most frequently by Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, and Pseudomonas aeruginosa (6); 2) treatment with ICS in patients with COPD increases bacterial load (7, 8); and 3) chronic bacterial colonization in patients with COPD is associated with an increase in the number and severity of exacerbations, accelerated decline of lung function, higher pneumonia incidence, worse quality of life, and higher mortality (6, 9), and these are the most common outcomes used in COPD trials. However, chronic airway infection is never measured or considered in most trials investigating the role of ICS in COPD. We propose, therefore, that future studies collect precise information on bacterial colonization before randomization and during follow-up. Sputum culture (quantitative if possible) is cheap and feasible (10) and can be obtained in a large proportion of patients. This information would likely help to determine which patients can benefit most from ICS or in whom their withdrawal would be safer.
  9 in total

1.  Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis.

Authors:  Miguel Angel Martinez-Garcia; Rosa Faner; Grace Oscullo; David de la Rosa; Juan-Jose Soler-Cataluña; Marta Ballester; Alvar Agusti
Journal:  Am J Respir Crit Care Med       Date:  2020-05-01       Impact factor: 21.405

2.  Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Authors:  David A Lipson; Frank Barnhart; Noushin Brealey; Jean Brooks; Gerard J Criner; Nicola C Day; Mark T Dransfield; David M G Halpin; MeiLan K Han; C Elaine Jones; Sally Kilbride; Peter Lange; David A Lomas; Fernando J Martinez; Dave Singh; Maggie Tabberer; Robert A Wise; Steven J Pascoe
Journal:  N Engl J Med       Date:  2018-04-18       Impact factor: 91.245

3.  Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD.

Authors:  Marco Contoli; Alessia Pauletti; Maria Rita Rossi; Antonio Spanevello; Paolo Casolari; Andrea Marcellini; Giacomo Forini; Giulia Gnesini; Brunilda Marku; Neil Barnes; Andrea Rizzi; Giacomo Curradi; Gaetano Caramori; Paolo Morelli; Alberto Papi
Journal:  Eur Respir J       Date:  2017-10-05       Impact factor: 16.671

Review 4.  The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD.

Authors:  Janice M Leung; Pei Yee Tiew; Micheál Mac Aogáin; Kurtis F Budden; Valerie Fei Lee Yong; Sangeeta S Thomas; Kevin Pethe; Philip M Hansbro; Sanjay H Chotirmall
Journal:  Respirology       Date:  2017-03-25       Impact factor: 6.424

5.  Impact of Pseudomonas aeruginosa Isolation on Mortality and Outcomes in an Outpatient Chronic Obstructive Pulmonary Disease Cohort.

Authors:  David M Jacobs; Heather M Ochs-Balcom; Katia Noyes; Jiwei Zhao; Wai Yin Leung; Chan Yeu Pu; Timothy F Murphy; Sanjay Sethi
Journal:  Open Forum Infect Dis       Date:  2020-01-04       Impact factor: 3.835

6.  The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.

Authors:  MeiLan K Han; Gerard J Criner; Mark T Dransfield; David M G Halpin; C Elaine Jones; Sally Kilbride; Peter Lange; Sally Lettis; David A Lipson; David A Lomas; Neil Martin; Robert A Wise; Dave Singh; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2020-11-01       Impact factor: 21.405

7.  Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease: Can IMPACT Help?

Authors:  Samy Suissa
Journal:  Am J Respir Crit Care Med       Date:  2020-11-01       Impact factor: 21.405

8.  Angels Dancing on the Tip of a Needle: Interpreting Clinical Trials in Chronic Obstructive Pulmonary Disease.

Authors:  Peter Calverley
Journal:  Am J Respir Crit Care Med       Date:  2020-11-01       Impact factor: 21.405

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.